Drugs / PF-07820435
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06285097 | Feb 2024 → Jan 2025 | colorectal carcinoma, head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma +3 | Pfizer | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07820435 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06285097 ↗ |
| Action | Activate | “immune agonist” NCT06285097 ↗ |
| Route | Oral | “Participants will receive PF-07820435 orally at the prescribed dose and frequency in 28-day cycles” NCT06285097 ↗ |